Table 3. Risks of Overall and Specific Cancers in Patients With Hidradenitis Suppurativa Compared With a Matched Control Cohort According to Age Group.

Cancer subtype	Age <40 y		Age ≥40 y
	Adjusted HR (95% CI)a	P value	Adjusted HR (95% CI)a	P value
Overall	1.34 (1.06-1.68)	.01	1.26 (1.11-1.42)	<.001
Oral cavity and pharyngeal	2.51 (0.52-12.10)	.25	3.26 (1.57-6.80)	.002
Esophageal	NE		1.51 (0.44-5.18)	.51
Gastric	1.01 (0.36-2.87)	.98	1.02 (0.74-1.41)	.91
Small intestine	NE		2.36 (0.49-11.40)	.29
Colorectal	1.68 (0.78-3.59)	.19	1.41 (1.04-1.93)	.03
Liver	1.48 (0.33-6.69)	.61	1.07 (0.69-1.67)	.76
Biliary	9.04 (0.56-145.02)	.12	1.17 (0.56-2.45)	.68
Pancreatic	NE		1.27 (0.63-2.57)	.50
Laryngeal	NE		0.59 (0.08-4.49)	.61
Lung	NE		1.34 (0.95-1.90)	.10
Bone and articular cartilage	1.34 (0.16-11.12)	.95	NE
Malignant melanoma skin	NE		1.75 (0.20-15.19)	.61
Nonmelanoma skin	2.79 (0.56-13.82)	.21	1.96 (1.02-3.80)	.045
Breast	1.23 (0.61-2.49)	.56	1.21 (0.74-1.99)	.45
Uterine cervical	0.44 (0.06-3.29)	.42	0.33 (0.05-2.47)	.28
Uterine corpus	NE		1.26 (0.28-5.60)	.76
Ovarian	1.62 (0.19-13.86)	.66	0.92 (0.21-3.94)	.91
Prostate	NE		2.05 (1.30-3.24)	.002
Testicular	1.03 (0.13-8.20)	.98	NE
Renal	1.65 (0.47-5.75)	.44	1.31 (0.59-2.91)	.51
Bladder	NE		0.60 (0.22-1.66)	.32
Central nervous system	3.05 (1.09-8.56)	.03	2.02 (0.83-4.93)	.12
Thyroid	1.27 (0.88-1.83)	.20	1.08 (0.69-1.68)	.75
Adrenal	NE		NE
Lymphoma	1.53 (0.44-5.31)	.50	1.73 (0.81-3.74)	.16
Hodgkin lymphoma	2.67 (0.28-25.69)	.40	9.04 (1.26-64.85)	.03
Non-Hodgkin lymphoma	1.27 (0.28-5.69)	.76	1.36 (0.57-3.25)	.49
Multiple myeloma	NE		1.65 (0.36-7.60)	.52
Leukemia	2.55 (1.02-6.39)	.046	0.45 (0.06-3.34)	.43

Abbreviations: HR, hazard ratio; NE, not estimated.

^aAdjusted for the presence of hypertension and dyslipidemia.